ORIC übertreffen die 12 der letzten 23Schätzungen.
52%
Nächster Bericht
Datum des nächsten Berichts
16. Feb. 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$0.36
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
+9.09%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-29.41%
Oric Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On 13. Nov. 2025, ORIC reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.41 USD, resulting in a 20.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.49% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an increase of 9.09% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Oric Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Oric Pharmaceuticals, Inc. Common Stock reported EPS of -$0.33, beating estimates by 20.14%, and revenue of $0.00, 0% as expectations.
How did the market react to Oric Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 0.49%, changed from $12.19 before the earnings release to $12.25 the day after.
When is Oric Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for 16. Feb. 2026.
What are the forecasts for Oric Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 17
analysts, Oric Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.